UCB Medicines: Clinical Studies and Scientific Research Publication
Publications
New Scientific Information: Click the respective link for peer-reviewed, phase 3 publications related to the unapproved uses of bimekizumab for Axial Spondyloarthritis, Psoriatic Arthritis, and Hidradenitis Suppurativa
BIMZELX® (bimekizumab-bkzx)
Bimekizumab self-injection devices: Two multicenter, randomized, open-label studies on self-administration by patients with psoriasis.
BIMZELX® (bimekizumab-bkzx)
Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: A systematic literature review and a network meta-analysis.
BIMZELX® (bimekizumab-bkzx)
Bimekizumab versus secukinumab in plaque psoriasis.
RYSTIGGO® (rozanolixizumab-noli)
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial
BIMZELX® (bimekizumab-bkzx)
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised trial.
BIMZELX® (bimekizumab-bkzx)
Bimekizumab versus adalimumab in plaque psoriasis.
BIMZELX® (bimekizumab-bkzx)
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
BIMZELX® (bimekizumab-bkzx)
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
CIMZIA® (certolizumab pegol)
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study.
ZILBRYSQ® (zilucoplan)
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial
BIMZELX® (bimekizumab-bkzx)
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.